| Added by | André Pèlegrin |
|---|---|
| Group name | EquipeAP |
| Item Type | Journal Article |
| Title | External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience |
| Creator | Griguolo et al. |
| Author | Gaia Griguolo |
| Author | William Jacot |
| Author | Eva Kantelhardt |
| Author | Maria Vittoria Dieci |
| Author | Céline Bourgier |
| Author | Christoph Thomssen |
| Author | Caroline Bailleux |
| Author | Federica Miglietta |
| Author | Antoine-Laurent Braccini |
| Author | PierFranco Conte |
| Author | Jean Marc Ferrero |
| Author | Valentina Guarneri |
| Author | Amélie Darlix |
| Abstract | BACKGROUND: Several prognostic scores have been developed to estimate survival of breast cancer (BC) patients with brain metastases (BM). Modified Breast Graded Prognostic Assessment (GPA), based on a single-institution cohort of 1552 patients, has been proposed as refinement of Breast-GPA. In addition to age, tumour subtype and KPS, Modified Breast-GPA comprises number of BM. This study was designed to validate Modified Breast-GPA. PATIENTS AND METHODS: Clinical data of 668 BC patients diagnosed with BM at four institutions between 1996 and 2016 were reviewed. Patients were classified by Breast-GPA and Modified Breast-GPA. Overall survival (OS) was calculated from time of BM diagnosis to death or last follow-up. Cox proportional models were used to calculate hazard-ratios and their 95% CI. The performances of Breast-GPA and Modified Breast-GPA were compared using Harrell's concordance index. RESULTS: Median age at BM diagnosis was 56 years (range 24-85). At last follow-up, 632 patients (94.6%) had died. Median OS was 8.1 months (95% CI 6.9-9.4). The number of BM (1-3 vs. >3) was significantly associated with OS in univariate analysis (p < 0.001) and having >3 BM was identified as a negative prognostic factor in multivariate analysis. Both Breast-GPA and Modified Breast-GPA accurately predicted OS (p < 0.001 for both scores). Performance of Modified Breast-GPA was better: concordance indices were 0.6390 (95% CI, 0.6381 to 0.6399) and 0.6647 (95% CI, 0.6639 to 0.6655) for Breast-GPA and Modified Breast-GPA, respectively (p < 0.001). CONCLUSIONS: This work provides the first external independent validation of Modified Breast-GPA and confirms its better performance as compared to Breast-GPA. |
| Publication | Breast (Edinburgh, Scotland) |
| Volume | 37 |
| Pages | 36-41 |
| Date | Feb 2018 |
| Journal Abbr | Breast |
| Language | eng |
| DOI | 10.1016/j.breast.2017.10.006 |
| ISSN | 1532-3080 |
| Short Title | External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases |
| Library Catalog | PubMed |
| Extra | PMID: 29073498 |
| Tags | Adult, Age Factors, Aged, Aged, 80 and over, Brain metastases, Brain Neoplasms, Breast Neoplasms, clinic, clinique hors équipe, Female, France, Germany, Graded Prognostic Assessment, Humans, Italy, Karnofsky Performance Status, Middle Aged, Modified Breast Graded Prognostic Assessment, nonvisible, Prognosis, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Retrospective Studies, Survival Rate, Tumor Burden, Young Adult |
| Date Added | 2018/08/28 - 11:20:01 |
| Date Modified | 2019/12/11 - 18:28:30 |
Institut de Recherche en Cancérologie de
